The business side of the industry, how well is it doing? is it profitable? What does the future hold?
Maya Health raised $4.3M to decentralize psychedelic research. The company is developing a blockchain-based platform that allows the psychedelic community to collaborate, share best practices, and gather real-world data to accelerate pre-clinical research.
MINDCURE’s (MCUR) digital therapeutics platform was certified as HIPAA compliant, meaning that it effectively protects sensitive patient data. The certification gets the company one step closer to commercially deploying the platform in Q2 of 2022.
COMPASS Pathways’ (CMPS) patent for crystalline psilocybin is being challenged by the non-profit Freedom to Operate. After conducting advanced analysis, the organization is confident that the formulation isn’t novel and has been known for decades.
Doseology Sciences Inc. (MOOD), a functional mushroom company, is preparing to expand into the psilocybin market with a recent application for a controlled substance Dealer’s License and a new addition to its research team. The company aims to develop and sell novel strains of psychedelic mushrooms once granted the license.
atai Life Sciences (ATAI) launched TryptageniX, a majority-owned joint venture with CB Therapeutics that will focus on discovering new compounds, both psychedelic and non-psychedelic.
An analyst at H.C. Wainwright predicted that Field Trip Health’s (FTRP) and COMPASS Pathways’ (CMPS) stocks could quadruple in value in the next 12 months! 🤑
Mycotopia Therapies (TPIA) is planning a $360M merger with Ei.Ventures to form PSLY.COM and intends to list on the NASDAQ. The new company would focus on Ei.Ventures’ flagship product Psilly, which combines psilocybin with other plant and fungi extracts for a synergistic effect.
Delic (DELC) launched a free, virtual education program to teach the families of ketamine therapy patients how they can best support their loved ones through the healing journey.
Way2Grow Biopharma, a private BC company, received a license from Health Canada to create a psychedelic production campus. The company can produce up to $30 worth of compounds to sell to pharmacies and clinics.
Mycotopia Therapies (TPIA) and Agile Pharmaceutical Solutions formed a joint venture to develop an oral psilocybin tablet for depression. The companies may work with HAVN Life Sciences (HAVN) in Jamaica for assistance with development and sourcing materials.
